Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
5 mg/kg CM-101
Chemomab Therapeutics
Nonalcoholic Steatohepatitis
1 trial -
5% Bisphosphocin Topical Gel
Lakewood-Amedex Biotherapeutics
Chronic Diabetic Foot Ulcers
1 trial -
5% Nu-3 gel
Lakewood-Amedex Biotherapeutics
Diabetic Foot Infection
1 trial -
5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac
Enliven Therapeutics
Solid Tumors, Colorectal Cancer and Breast Cancer
1 trial -
5-Fluorouracil (5-FU)
HALOZYME THERAPEUTICS, INC.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
1 trial -
60 mg Prednisone
United Therapeutics Europe Ltd
Airway Inflammation
1 trial -
626
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Systemic Lupus Erythematosus (SLE)
1 trial -
68Ga-DOTATATE and 68Ga-FAPI
The First People's Hospital of Lianyungang
Tumor Positron-Emission Tomography
1 trial -
68Ga-FAP-CHX
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-FAPI-46
Istituto Gentili S.r.l.
oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT
1 trial -
68Ga-FAPI-46
The George Institute
Triple-negative breast cancer (TNBC) patients at high risk of relapse
1 trial -
68Ga-FAPI-46
The George Institute
Non-metastatic Pancreatic ductal adenocarcinoma
1 trial -
68Ga-FAPI-46, Sonelokimab
MoonLake Immunotherapeutics
psoriatic arthritis, axial spondyloarthritis
1 trial -
68Ga-G21
The First People's Hospital of Lianyungang
Prostate Cancer (Adenocarcinoma)
1 trial -
68Ga-NY104 PET/CT
The First People's Hospital of Lianyungang
Clear Cell Renal Cell Carcinoma
1 trial -
70 mL red beetroot juice
United Therapeutics Europe Ltd
Overweight
1 trial -
89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Cancer
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Pancreatic Adenocarcinoma
1 trial -
9-ING-41
ACTUATE THERAPEUTICS, INC.
Salivary Gland Carcinoma
1 trial -
A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Advanced or metastatic squamous cell carcinoma of the esophagus
1 trial -
A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy
Sanofi-aventis Healthcare Pty Ltd
Type 1 diabetes mellitus
1 trial -
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress
Seaport Therapeutics
Major Depressive Disorder (MDD), with or without Anxious Distress
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources